p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab

p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab

Abstract The PI3K-Akt-mTOR (PAM) pathway is implicated in tumor progression in many tumor types, including metastatic gastric cancer (GC). The initial promise of PAM inhibitors has been unrealized in the clinic, presumably due, in part, to the up-regulation of Akt signaling that occurs when the path...

Full description

Bibliographic Details
Main Authors: Shota Fukuoka, Yoshikatsu Koga, Mayumi Yamauchi, Shigehiro Koganemaru, Masahiro Yasunaga, Kohei Shitara, Toshihiko Doi, Takayuki Yoshino, Toshio Kuronita, Brian Elenbaas, Pamela Wahra, Hong Zhang, Lindsey Crowley, Molly H. Jenkins, Anderson Clark, Takashi Kojima
Format: Article
Language:English
Published: Nature Portfolio 2023-09-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-40612-9

Internet

https://doi.org/10.1038/s41598-023-40612-9

Similar Items